|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPARGC1B |
Gene summary for PPARGC1B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPARGC1B | Gene ID | 133522 |
| Gene name | PPARG coactivator 1 beta | |
| Gene Alias | ERRL1 | |
| Cytomap | 5q32 | |
| Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | B7ZM40 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 133522 | PPARGC1B | CCI_2 | Human | Cervix | CC | 7.85e-07 | 8.17e-01 | 0.5249 |
| 133522 | PPARGC1B | CCI_3 | Human | Cervix | CC | 3.18e-03 | 4.14e-01 | 0.516 |
| 133522 | PPARGC1B | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.44e-10 | -4.74e-01 | 0.0155 |
| 133522 | PPARGC1B | HTA11_347_2000001011 | Human | Colorectum | AD | 7.88e-06 | 5.02e-01 | -0.1954 |
| 133522 | PPARGC1B | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.08e-02 | -3.96e-01 | -0.1207 |
| 133522 | PPARGC1B | HTA11_866_3004761011 | Human | Colorectum | AD | 9.53e-09 | -6.05e-01 | 0.096 |
| 133522 | PPARGC1B | HTA11_6818_2000001021 | Human | Colorectum | AD | 3.18e-02 | -4.51e-01 | 0.0588 |
| 133522 | PPARGC1B | HTA11_99999970781_79442 | Human | Colorectum | MSS | 9.29e-12 | -4.83e-01 | 0.294 |
| 133522 | PPARGC1B | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.53e-21 | -6.39e-01 | 0.3859 |
| 133522 | PPARGC1B | HTA11_99999973899_84307 | Human | Colorectum | MSS | 8.46e-04 | -6.55e-01 | 0.2585 |
| 133522 | PPARGC1B | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.27e-32 | -8.01e-01 | 0.3005 |
| 133522 | PPARGC1B | F007 | Human | Colorectum | FAP | 1.20e-10 | -6.72e-01 | 0.1176 |
| 133522 | PPARGC1B | A002-C-010 | Human | Colorectum | FAP | 1.42e-07 | -5.15e-01 | 0.242 |
| 133522 | PPARGC1B | A001-C-207 | Human | Colorectum | FAP | 5.47e-21 | -7.78e-01 | 0.1278 |
| 133522 | PPARGC1B | A015-C-203 | Human | Colorectum | FAP | 2.36e-32 | -5.99e-01 | -0.1294 |
| 133522 | PPARGC1B | A015-C-204 | Human | Colorectum | FAP | 1.26e-08 | -4.46e-01 | -0.0228 |
| 133522 | PPARGC1B | A014-C-040 | Human | Colorectum | FAP | 4.17e-08 | -7.06e-01 | -0.1184 |
| 133522 | PPARGC1B | A002-C-201 | Human | Colorectum | FAP | 6.75e-25 | -7.00e-01 | 0.0324 |
| 133522 | PPARGC1B | A002-C-203 | Human | Colorectum | FAP | 5.14e-17 | -6.15e-01 | 0.2786 |
| 133522 | PPARGC1B | A001-C-119 | Human | Colorectum | FAP | 2.84e-22 | -8.43e-01 | -0.1557 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
| GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
| GO:000030210 | Cervix | CC | response to reactive oxygen species | 56/2311 | 222/18723 | 1.00e-07 | 5.25e-06 | 56 |
| GO:006219710 | Cervix | CC | cellular response to chemical stress | 76/2311 | 337/18723 | 1.01e-07 | 5.25e-06 | 76 |
| GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
| GO:004854510 | Cervix | CC | response to steroid hormone | 74/2311 | 339/18723 | 5.71e-07 | 2.09e-05 | 74 |
| GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
| GO:003459910 | Cervix | CC | cellular response to oxidative stress | 63/2311 | 288/18723 | 3.58e-06 | 9.50e-05 | 63 |
| GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
| GO:19021056 | Cervix | CC | regulation of leukocyte differentiation | 61/2311 | 279/18723 | 5.16e-06 | 1.29e-04 | 61 |
| GO:004563710 | Cervix | CC | regulation of myeloid cell differentiation | 48/2311 | 210/18723 | 1.49e-05 | 2.93e-04 | 48 |
| GO:00018949 | Cervix | CC | tissue homeostasis | 57/2311 | 268/18723 | 2.43e-05 | 4.21e-04 | 57 |
| GO:00025738 | Cervix | CC | myeloid leukocyte differentiation | 47/2311 | 208/18723 | 2.48e-05 | 4.27e-04 | 47 |
| GO:00456397 | Cervix | CC | positive regulation of myeloid cell differentiation | 28/2311 | 103/18723 | 3.56e-05 | 5.70e-04 | 28 |
| GO:00319609 | Cervix | CC | response to corticosteroid | 39/2311 | 167/18723 | 5.48e-05 | 8.06e-04 | 39 |
| GO:00602498 | Cervix | CC | anatomical structure homeostasis | 63/2311 | 314/18723 | 6.03e-05 | 8.68e-04 | 63 |
| GO:00513849 | Cervix | CC | response to glucocorticoid | 35/2311 | 148/18723 | 9.87e-05 | 1.27e-03 | 35 |
| GO:003530310 | Cervix | CC | regulation of dephosphorylation | 31/2311 | 128/18723 | 1.52e-04 | 1.83e-03 | 31 |
| GO:003461410 | Cervix | CC | cellular response to reactive oxygen species | 35/2311 | 155/18723 | 2.59e-04 | 2.85e-03 | 35 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04931 | Colorectum | MSS | Insulin resistance | 36/1875 | 108/8465 | 4.74e-03 | 2.01e-02 | 1.23e-02 | 36 |
| hsa049311 | Colorectum | MSS | Insulin resistance | 36/1875 | 108/8465 | 4.74e-03 | 2.01e-02 | 1.23e-02 | 36 |
| hsa049312 | Colorectum | FAP | Insulin resistance | 32/1404 | 108/8465 | 4.90e-04 | 3.56e-03 | 2.16e-03 | 32 |
| hsa049313 | Colorectum | FAP | Insulin resistance | 32/1404 | 108/8465 | 4.90e-04 | 3.56e-03 | 2.16e-03 | 32 |
| hsa049314 | Colorectum | CRC | Insulin resistance | 28/1091 | 108/8465 | 1.78e-04 | 2.37e-03 | 1.61e-03 | 28 |
| hsa049315 | Colorectum | CRC | Insulin resistance | 28/1091 | 108/8465 | 1.78e-04 | 2.37e-03 | 1.61e-03 | 28 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPARGC1B | SNV | Missense_Mutation | novel | c.2272C>T | p.His758Tyr | p.H758Y | Q86YN6 | protein_coding | deleterious(0.01) | possibly_damaging(0.869) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| PPARGC1B | SNV | Missense_Mutation | c.2455N>T | p.Asp819Tyr | p.D819Y | Q86YN6 | protein_coding | deleterious(0.01) | possibly_damaging(0.751) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PPARGC1B | SNV | Missense_Mutation | novel | c.2773N>A | p.Phe925Ile | p.F925I | Q86YN6 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PPARGC1B | SNV | Missense_Mutation | novel | c.398N>T | p.Ser133Phe | p.S133F | Q86YN6 | protein_coding | deleterious(0.05) | possibly_damaging(0.823) | TCGA-AR-A2LH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| PPARGC1B | SNV | Missense_Mutation | novel | c.759N>G | p.Asp253Glu | p.D253E | Q86YN6 | protein_coding | tolerated(0.17) | probably_damaging(0.991) | TCGA-B6-A2IU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| PPARGC1B | SNV | Missense_Mutation | c.2384N>A | p.Ser795Asn | p.S795N | Q86YN6 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-BH-A0W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR | |
| PPARGC1B | SNV | Missense_Mutation | c.200N>C | p.Asn67Thr | p.N67T | Q86YN6 | protein_coding | tolerated(0.22) | benign(0) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PPARGC1B | SNV | Missense_Mutation | rs559196017 | c.431N>T | p.Ser144Leu | p.S144L | Q86YN6 | protein_coding | tolerated(0.53) | benign(0) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD |
| PPARGC1B | insertion | Frame_Shift_Ins | novel | c.2273_2274insGGATGGAAGGTGGATT | p.His758GlnfsTer7 | p.H758Qfs*7 | Q86YN6 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| PPARGC1B | insertion | Frame_Shift_Ins | novel | c.2232_2233insTTTTCTTT | p.Ala745PhefsTer14 | p.A745Ffs*14 | Q86YN6 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |